Get In Touch
Get In Touch
Sygnature Discovery > Drug Discovery > DMPK > DMPK Consultancy

DMPK Consultancy

Sygnature Discovery offers a range of DMPK consultancy services to drug discovery research teams within the academic, pharmaceutical, biotechnology, charity and CRO sectors, as well as to life science venture capital funds. We can work as a stand-alone function or as an integral part of the drug discovery project team.

Services include:

  • DMPK consultancy from Hit ID right through to Candidate Nomination.
  • Strength in providing DMPK input into CNS discovery projects.
  • Independent expert DMPK reviews of ongoing discovery projects.
  • Expertise in integrating DMPK into early drug discovery.
  • Problem-solving abilities around ADME and PK.
  • Review and unbiased critique of research proposals.
  • Third party due diligence of DMPK packages for in-licensing opportunities.
Get In Touch

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.

Opt In *

Other Related Services

Physicochemical Profiling

It is well understood that poor physicochemical properties are associated with increased failure of drug candidates within the pre-clinical and clinical development process. Assessing these parameters during the discovery optimisation process is critical.

DISCOVER

In silico and PBPK modelling

Sygnature uses the GastroPlusTM software package that simulates absorption, distribution, metabolism and elimination in humans and animals from a range of dose routes including oral, intravenous, inhaled, ocular and dermal. This enables data integration within the context of a virtual animal or human model.

DISCOVER

In Vitro ADME

The assessment of the Absorption, Distribution, Metabolism, and Excretion (ADME) properties of compounds is a critical component is supporting the development of compounds within Discovery and Development. 

DISCOVER

In Vivo Pharmacokinetics (PK)

At Sygnature Discovery we offer services to support your non-GLP in vivo Pharmacokinetics studies in preclinical species including the planning of these studies and the analysis of any samples generated by UPLC-MS

DISCOVER

Bioanalysis

Sygnature’s state-of-the-art non-GLP bioanalysis service brings together the latest instrumentation and technology, which, combined with the wealth of experience across the team, is used to provide quantitative measures of metabolites for the purpose of pharmacokinetics, toxicokinetics, bioequivalence and exposure-response studies.

DISCOVER

Metabolite Identification (Met-ID)

Sygnature’s DMPK and biotransformational capabilities are supplemented by extensive expertise in complementary analytical techniques, including high-resolution mass spectrometry, nuclear magnetic resonance, chemically intelligent software algorithms and mass spectrometry imaging.

DISCOVER